Quality use of medicines within universal health coverage: Challenges and opportunities

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Wagner, Anita K ^a   Quick, Jonathan D ^b   Ross Degnan, Dennis ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MANAGEMENT SCIENCES FOR HEALTH   (United States)

Author keywords

Financial incentives; Health systems; Medicines; Pharmaceutical benefit; Quality of care; Universal health coverage

Indexed keywords

ECONOMICS; HUMAN; INSURANCE; MEDICATION THERAPY MANAGEMENT; QUALITY CONTROL; REIMBURSEMENT; STANDARDS;

HUMANS; MEDICATION THERAPY MANAGEMENT; QUALITY CONTROL; REIMBURSEMENT, INCENTIVE; UNIVERSAL COVERAGE;

EID: 84906962383     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-357     Document Type: Article

References (30)

1. Chan M, Remarks at the Launch of the World Health Report 2013: Research for Universal Health Coverage Beijing 2013 [Cited 10 September 2013]. Available from: http://www.who.int/dg/speeches/2013/whr-20130815/en/index.html
2. The global use of medicines. Outlook through 2017. IMS Institute for Healthcare Informatics, [Cited 22 August 2014]. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global-Use-of-Meds-Outlook-2017/IIHI-Global-Use-of-Meds-Report-2013.pdf
3. Lu Y, Hernandez P, Abegunde D, Edejer T, The World Medicines Situation 2011: Medicine Expenditures Geneva: World Health Organization [Cited 22 August 2014]; Available from: http://apps.who.int/medicinedocs/documents/s18767en/s18767en.pdf
4. World Health Report, Health Systems Financing: The Path to Universal Coverage Geneva: World Health Organization 2010 [Cited 01 April 2013]. Available from: http://www.who.int/whr/2010/en/index.html
5. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved. Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO, Value Health 2012 15 5 664 673 10.1016/j.jval.2012.04.004 22867775
6. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, Ewen M, Bull World Health Organ 2007 85 4 279 288 [Cited 22 August 2014] http://www.who.int/bulletin/volumes/85/4/06-033647.pdf 10.2471/BLT.06.033647 17546309
7. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO, Bull World Health Organ 2011 89 6 412 421 [Cited 22 August 2014] http://www.who.int/bulletin/volumes/89/6/10-084327.pdf 10.2471/BLT.10.084327 21673857
8. Buckley GJ, Gostin LO, Countering the Problem of Falsified and Substandard Drugs Washington: Institute of Medicine 2013 [Cited 21 March 2013] http://www.iom.edu/Reports/2013/Countering-the-Problem-of-Falsified-and-Substandard-Drugs.aspx
9. World Health Organization, Medicines use in Primary Care in Developing and Transitional Countries. Fact Book Summarizing Results from Studies Reported Between 1990 and 2006 Geneva: World Health Organization 2009 [Cited 01 April 2013]. Available from:http://apps.who.int/medicinedocs/documents/s16073e/s16073e.pdf
10. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, Prospective Urban Rural Epidemiology (PURE) Study Innvestigators, Lancet 2011 378 9798 1231 1242 10.1016/S0140-6736(11)61215-4 21872920
11. A systematic review of adherence to cardiovascular medications in resource-limited settings. Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK, J Gen Intern Med 2011 26 12 1479 1491 10.1007/s11606-011-1825-3 21858602
12. Insured yet vulnerable: out-of-pocket payments and India's poor. Shahrawat R, Rao KD, Health Policy Plan 2012 27 3 213 221 10.1093/heapol/czr029 21486910
13. Non evidence-based policy: How effective is China's new cooperative medical scheme in reducing medical impoverishment? Yip W, Hsiao W, Soc Sci Med 2009 68 2 201 209 10.1016/j.socscimed.2008.09.066 19019519
14. Commissioner's report. UN Commission on Life-Saving Commodities for Women and Children, 2012 [Cited 01 June 2013]. Available from: http://www.unicef.org/media/files/UN-Commission-Report-September-2012-Final.pdf
15. Problems paying out-of-pocket medication costs among older adults with diabetes. Piette JD, Heisler M, Wagner TH, Diabetes Care 2004 27 2 3 391 doi:10.2337/diacare.27.2.384
16. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner AK, Health Policy 2011 100 134 143 10.1016/j.healthpol.2010.10.020 21185616
17. Health insurance systems in five Sub-Saharan African countries: medicines benefits and data for decision making. Carapinha J, Ross-Degnan D, Desta A, Wagner AK, Health Policy 2011 99 193 202 10.1016/j.healthpol.2010.11.009 21167619
18. Backliwal A, Mani S, Navigating the new Thailand IMS Asia Pacific Insight 2011. 2011 1:12-15. [Cited 22 August 2014]; Available from: http://www.imshealth.com/deployedfiles/ims/Global/Asia%20Pacific/2011-Magazine-Asia-softcopy%20FINAL.pdf
19. World Health Organization, Global Health Observatory [Cited 01 June 2013]. Available from: http://www.who.int/gho/en/
20. Published clinical guidelines. National Institute for Health and Care Excellence, [Cited 01 June 2013]. Available from: http://www.nice.org.uk/guidance/cg/published/index.jsp?p=off
21. Moving forward on rationing. Various authors (BMJ Special Section), BMJ 2008 337 903 906 10.1136/bmj.a903
22. Quality assurance and safety of medicines: Main challenges and strategic direction. World Health Organization, [Cited 01 June 2013]. Available from: http://www.who.int/medicines/about/qsm-strategy/en/
23. Managing access to medicines and health technologies (MDS-3). Management Sciences for Health: MDS-3, Arlington, VA: Management Sciences for Health 2012 [Cited 22 August 2014]. Available from: http://www.msh.org/resources/mds-3-managing-access-to-medicines-and-health-technologies
24. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H, Cochrane Database Syst Rev 2006 19 2 D005979
25. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, Kösters JP, Vernby A, Cochrane Database Syst Rev 2008 23 1 D007017
26. Pharmaceutical policies: effects of financial incentives for prescribers. Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, Kösters JP, Cochrane Database Syst Rev 2007 18 3 D006731
27. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature-2001-2007. Lu CY, Ross-Degnan D, Soumerai SB, Pearson S-A, BMC Health Serv Res 2008 8 1 75 10.1186/1472-6963-8-75 18394200
28. Essential medicines [Cited 11 July 2013]. World Health Organization, Available from: http://www.who.int/topics/essential-medicines/en/
29. Societal views on NICE, cancer drugs fund, and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Linley WG, Hughes DA, Health Econ 2013 22 948 964 10.1002/hec.2872 22961976
30. Systems thinking for health systems strengthening in LMICs: seizing the opportunity. Adam T, De Savigny D, Health Policy Plann 2012 27 Suppl 4 v1 iv66